Role of red grape polyphenols as antidiabetic agents

Kanti Bhooshan Pandey1, Syed Ibrahim Rizvi1

  • 1Department of Biochemistry, University of Allahabad, Allahabad, India.

Insights

Polyphenols like quercetin, myricetin, and resveratrol from red grapes may help prevent diabetic complications. These natural compounds combat oxidative stress, a key factor in hyperglycemia and its damaging effects.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Nutritional Science

Background:

  • Diabetes mellitus incidence is rising globally, leading to severe health complications.
  • Persistent hyperglycemia contributes to damage in vital organs like the retina, brain, and kidneys.
  • Oxidative stress is a critical factor in the development and progression of diabetic complications.

Purpose of the Study:

  • To review the role of major red grape polyphenols (quercetin, myricetin, resveratrol) in mitigating diabetic complications.
  • To provide an update on their comparative efficacy.
  • To highlight the molecular mechanisms of oxidative stress in hyperglycemia.

Main Methods:

  • Literature review focusing on studies of quercetin, myricetin, and resveratrol.
  • Analysis of research on oxidative stress and hyperglycemia.
  • Comparative assessment of polyphenol efficacy against diabetic pathologies.

Main Results:

  • Quercetin, myricetin, and resveratrol show potential in preventing or managing diabetic complications.
  • These polyphenols exert protective effects through mechanisms related to oxidative stress.
  • Evidence supports their role in combating hyperglycemia-associated pathologies.

Conclusions:

  • Red grape polyphenols offer a promising natural approach to managing diabetes complications.
  • Targeting oxidative stress is a key strategy for intervention.
  • Further research into these compounds could lead to novel therapeutic strategies.

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
672
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
739
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
786
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
758
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
4.7K